Prilocaine
Brand names: Citanest, EMLA (with lidocaine)
Prilocaine is an amide local anaesthetic used for infiltration, regional and intravenous regional anaesthesia, and as a topical agent in combination preparations.
Adult dose
Paediatric dose
Dose adjustments
No numerical renal dose adjustment is given. SPC 4.4: in common with other local anaesthetics, prilocaine hydrochloride should be used cautiously in the elderly, patients in poor health, and patients with liver or kidney damage, if the dose or site of administration is likely to result in high blood levels.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance, to anaesthetics of the amide type, or to any of the excipients
- Hypersensitivity to methyl and/or propyl parahydroxybenzoate (methyl-/propyl paraben) or to their metabolite para-aminobenzoic acid (PABA) — paraben-containing prilocaine formulations should be avoided in patients allergic to ester local anaesthetics or to PABA
- Should be avoided in patients with anaemia or congenital or acquired methaemoglobinaemia
Side effects
- Very common: hypotension and nausea (both occur more frequently after epidural blocks); common vomiting and hypertension
- Common: paraesthesia and dizziness; uncommon signs and symptoms of CNS toxicity; rare neuropathy and peripheral nerve injury
- Common bradycardia; rare cardiac arrest and cardiac arrhythmias; respiratory depression (frequency not known)
- Rare: methaemoglobinaemia and cyanosis (cyanosis in the presence of methaemoglobinaemia)
- Rare: allergic reactions including urticaria, oedema and dyspnoea, and anaphylactic reactions; diplopia (frequency not known)
- Acute systemic toxicity from high blood concentrations: a graded CNS response beginning with circumoral paraesthesia, numbness of the tongue, light-headedness, hyperacusis, tinnitus and visual disturbances, progressing through dysarthria, muscular twitching or tremors to generalised convulsions, unconsciousness and cardiovascular collapse
Interactions
- Class III anti-arrhythmic drugs (e.g. amiodarone) — patients should be under close surveillance and ECG monitoring should be considered, since cardiac effects may be additive (SPC 4.4, cross-referring to 4.5)
- Drugs known to cause methaemoglobinaemia (e.g. sulphonamides) — methaemoglobinaemia may occur at lower doses of prilocaine in patients receiving such concomitant therapy (SPC 4.4)
- This interaction list may be incomplete — check the full SPC.
Clinical monograph
How it works
It reversibly blocks voltage-gated sodium channels in nerve membranes, preventing depolarisation and the propagation of action potentials.
Prescribing in practice
- Excessive doses can cause methaemoglobinaemia through a metabolite, so it is used with particular caution in those susceptible, and methylthioninium chloride is the treatment for significant methaemoglobinaemia.
- As with all local anaesthetics, inadvertent intravascular injection or overdose can cause systemic central nervous system and cardiac toxicity.
- It is often regarded as relatively favourable for intravenous regional anaesthesia, but the maximum safe dose must always be calculated for the individual patient.
Monitoring
Monitor for signs of local anaesthetic systemic toxicity and for cyanosis or low oxygen saturations suggesting methaemoglobinaemia.
Counselling the patient
- Report dizziness, perioral tingling, ringing in the ears or a metallic taste, which can be early signs of toxicity.
- Bluish discolouration of the lips or skin should be reported immediately.
Evidence & guidelines
Its association with methaemoglobinaemia and its use in regional anaesthesia are well documented in standard anaesthetic references and the SPC.
Reference: AAGBI IV Regional Anaesthesia Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Rapid Sequence Induction (RSI) · DAS 2015 / AAGBI
- ICU Sedation and Analgesia · SCCM / NICE CG83
- Vasopressor Escalation in Shock · Surviving Sepsis Campaign 2021
- Tracheostomy Management · NTSP / ICS guidelines
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Anaphylaxis Under Anaesthesia · AAGBI 2018; NAP6